CLUSTER filed Feb 22, 2026 at 19:00 ET
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a concentrated 7-day window, including the Chief Development Officer, CFO, and Chief Commercial Officer, realizing over $157,000 in total proceeds. The transactions include both cash sales and share movements (M) with no stated value, suggesting possible pre-arranged 10b5-1 plans or equity settlements. The cluster of insider selling by top executives raises caution despite lack of explicit negative filing disclosures.